纳非莫司他介导的抑制 SARS-CoV-2 核糖体移码不足以损害 Vero 细胞中的病毒复制。评 Munshi 等人在广谱冠状病毒中鉴定 -1 程序性核糖体移码的抑制剂。2022 年， ，177.
Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. 2022, , 177.
机构信息
Infection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, 37077 Göttingen, Germany.
Faculty of Biology and Psychology, Georg-August-University, 37073 Göttingen, Germany.
出版信息
Viruses. 2022 Jul 13;14(7):1526. doi: 10.3390/v14071526.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, which has been reported to have caused 18 [...].
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是正在发生的 2019 年冠状病毒病（COVID-19）大流行的病原体，据报道，该病毒已造成 18 亿[...]人死亡。
Zotero 插件